Home › Research › Mild cognitive impairment
Preclinical Alzheimer's disease: diagnosis and prediction of progression
Chong MS, Sahadevan S.. The Lancet. Neurology, 2005-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background From the modest but important breakthroughs in the treatment of Alzheimer's disease (AD), diagnostic focus has increasingly shifted to the accurate detection of the earliest phase of the illness. The challenge of distinguishing preclinical AD from changes of normal ageing or established AD, has been recognised in several attempts at clinical classification. Of these attempts, Mayo Clinic's mild cognitive impairment (MCI) has received significant attention, although it has not been internationally accepted. Not all people diagnosed as having MCI will develop AD, hence there is a need to reliably predict progression. Recent developments Research in the identification of people with MCI who will develop AD via the use of neuropsychological tests, neuroimaging (both structural and functional), CSF analysis, and other biomarkers, either in isolation or in combination, has progressed rapidly. In this article we summarise findings from relevant recent longitudinal studies. WHERE NEXT?: There are increasing calls to recognise the pathological nature of MCI and to develop international diagnostic guidelines. Such uniform application of MCI criteria can then lead to clearer evidence of its diagnostic and therapeutic benefit. In developing these guidelines, the crucial presence of functional deficit arising from cognitive decline (which diagnoses dementia and excludes MCI) needs to be investigated in a standardised manner. Also needed are good-quality normal-values data on the various tests used to predict progression in preclinical AD.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This review discusses challenges in diagnosing preclinical Alzheimer's disease and predicting who with mild cognitive impairment will develop it. It reports no treatment or prevention results.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chong, M. S., & Sahadevan, S. (2005). Preclinical Alzheimer's disease: diagnosis and prediction of progression. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(05)70168-x
Vancouver
Chong MS, Sahadevan S. Preclinical Alzheimer's disease: diagnosis and prediction of progression. The Lancet. Neurology. 2005. doi:10.1016/s1474-4422(05)70168-x. PMID: 16109364.
BibTeX
@article{chong2005-16109364,
author = {Chong, M. S. and Sahadevan, S.},
title = {{Preclinical Alzheimer's disease: diagnosis and prediction of progression}},
journal = {The Lancet. Neurology},
year = {2005},
doi = {10.1016/s1474-4422(05)70168-x},
pmid = {16109364},
url = {https://doi.org/10.1016/s1474-4422(05)70168-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Of these attempts, Mayo Clinic's mild cognitive impairment (MCI) has received significant attention, although it has not been internationally accepted.
Why it matters
This review discusses challenges in diagnosing preclinical Alzheimer's disease and predicting who with mild cognitive impairment will develop it. It reports no treatment or prevention results.
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 50/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 172 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.5 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 3 / 6 | Cited 7.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 2 / 4 | Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Suresh Sahadevan: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Tan Tock Seng Hospital: institution h-index 292 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16109364) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Mild cognitive impairment from nearby years
Also in Mild cognitive impairment
76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.